Clinical Trial Update: Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating dovitinib for FGFR1-amplified squamous non-small cell lung cancer; the current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dovitinib (dovitinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Squamous NSCLC | Phase 2 | Status: UNKNOWN